MedTrace Logo

Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)

NCT07449520 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-03-04

No results posted yet for this study

Summary

EGO-Trial is the first multicenter study in France which aims to evaluate the efficacy of Endoscopic Sleeve Gastroplasty (ESG) in patients with obesity. This project fills a critical national gap by providing real-world, multicentric data from diverse French healthcare settings, offering insight into the safety, efficacy, and variability of ESG practices across institutions

The project is expected to generate robust, multicentric clinical evidence on the safety and efficacy of ESG in patients with obesity within the French healthcare context.

Conditions

Interventions

PROCEDURE

Endoscopic sleeve gastroplasty

Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device which allows for a reduction in stomach volume without resection or anastomosis

Sponsors & Collaborators

  • SOFF.COMM

    collaborator UNKNOWN

  • Boston Scientific International S.A.

    collaborator UNKNOWN

  • IHU Strasbourg

    lead OTHER

Principal Investigators

  • Silvana PERRETTA, MD-PhD · Hôpitaux Universitaires de Strasbourg

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2030-03-31
Completion
2030-03-31

Countries

  • France
  • Guadeloupe

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07449520 on ClinicalTrials.gov